221 related articles for article (PubMed ID: 31395668)
1. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.
Ahlawat S; Baig A; Blakeley JO; Jacobs MA; Fayad LM
J Magn Reson Imaging; 2016 Oct; 44(4):794-803. PubMed ID: 26991037
[TBL] [Abstract][Full Text] [Related]
4. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the "target sign" by diffusion weighted imaging.
Ahlawat S; Fayad LM
Eur J Radiol; 2018 May; 102():195-201. PubMed ID: 29685535
[TBL] [Abstract][Full Text] [Related]
5. Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI.
Yun JS; Lee MH; Lee SM; Lee JS; Kim HJ; Lee SJ; Chung HW; Lee SH; Shin MJ
Eur Radiol; 2021 Mar; 31(3):1548-1557. PubMed ID: 32894357
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.
Well L; Salamon J; Kaul MG; Farschtschi S; Herrmann J; Geier KI; Hagel C; Bockhorn M; Bannas P; Adam G; Mautner VF; Derlin T
Neuro Oncol; 2019 Mar; 21(4):508-516. PubMed ID: 30496452
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
10. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
[TBL] [Abstract][Full Text] [Related]
11. Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden.
Özden C; Mautner VF; Farschtschi S; Molwitz I; Ristow I; Bannas P; Well L; Klutmann S; Adam G; Apostolova I; Buchert R
J Neuroimaging; 2024; 34(1):138-144. PubMed ID: 37942683
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
13. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
[TBL] [Abstract][Full Text] [Related]
15. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
[TBL] [Abstract][Full Text] [Related]
17. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
18. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
[TBL] [Abstract][Full Text] [Related]
19. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.
Demehri S; Belzberg A; Blakeley J; Fayad LM
AJNR Am J Neuroradiol; 2014 Aug; 35(8):1615-20. PubMed ID: 24763412
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors.
Koike H; Nishida Y; Ito S; Shimoyama Y; Ikuta K; Urakawa H; Sakai T; Shimizu K; Ito K; Imagama S
World Neurosurg; 2022 Jan; 157():e207-e214. PubMed ID: 34624521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
